Summary Cell kinetics have been shown to be an important predictor of clinical evolution of operated breast cancer. We established a method for the estimation of the proliferative activity of tumour cells obtained by fine needle sampling without aspiration (FNS), using simultaneously S-phase fractions (SPF) measured on DNA histograms and 5-bromodeoxyuridine (BrdU) labelling index (BLI) Proliferative activity has consistently been found to be an important biological predictor of the clinical evolution of breast cancer (Tubiana et al., 1984; Silvestrini et al., 1985; Meyer, 1986; Hery et al., 1987) . Traditionally, it has been measured by autoradiography of a radiolabelled precursor (3H-thymidine) incorporated in tumour-cell DNA.
Proliferative activity has consistently been found to be an important biological predictor of the clinical evolution of breast cancer (Tubiana et al., 1984; Silvestrini et al., 1985; Meyer, 1986; Hery et al., 1987) . Traditionally, it has been measured by autoradiography of a radiolabelled precursor (3H-thymidine) incorporated in tumour-cell DNA.
With the introduction of DNA flow cytometry (FCM), fast cell-cycle distribution analysis of large numbers of cells has become available (Barlogie et al., 1982) . Retrospective studies have shown that S-phase fraction (SPF), computed from DNA histograms, is also a significant prognostic factor (Hedley et al., 1987; Kallioniemi et al., 1988 ) and a good predictor of response to neo-adjuvant chemotherapy (Remvikos et al., 1989) . Nevertheless, the possibility of establishing SPF's correctly has been questioned, either from poor quality-or complex histograms presenting multiple aneuploid peaks (Meyer et al., 1984; Kallioniemi et al., 1985) .
Although 3H-thymidine incorporation in fine needle aspirates was attempted in the late 70's (Nordenskjold et al., 1976) , very few data have been published on the use of cytology for the study of breast cancer proliferation. On the other hand, fine needle samplings (FNS) have been shown to be suitable for DNA FCM (Spyratos et al., 1987; Remvikos et al., 1988) . The measurement of proliferation in cytological samples presents a number of advantages. FNS can be obtained from patients at any stage of the disease, including non-operable tumours (Zajdela et al., 1987) . The information thus obtained, practically at the time of diagnosis, can be available for treatment decision. FNS are relatively nontraumatic and can be repeated during the treatment to monitor its efficacy.
In a prospective study of feasibility, we developed complementary methods for assaying SPF and BrdU labelling index (BLI) in vitro on the same tumour samples. Indeed, the substitution of 5-bromodeoxyuridine (BrdU) to 3H-thymidine has been proposed as a more convenient method of measuring DNA synthesis, due to the instant immunofluorimetric detection (Dolbeare et al., 1983; Schutte et al., 1987) . Tumour cells were obtained directly from the patients by fine needle sampling without aspiration. The inherent difficulties of each methodology are discussed in order to define the best approach for an adequate estimation of the proliferative activity of each breast cancer before treatment decision.
Materials and methods
One hundred and eighty-nine consecutive patients were subjected to fine needle sampling without aspiration, using 23 or 25 gauge needles (Zajdela et al., 1987 (Baisch et at., 1982) (Magdelenat et al., 1987a,b) . Figure 6 . The mean for the 141 cases was of 4.5% and the median of 3.5% (range 0.4-13.5%). A slightly different distribution was obtained for BLIs ( Figure 7) , with under-representation of the 7-9% values. The mean was of 3.0% and the median of 2.2% (range 0.3-17.4%).
SPF and BLI were obtained from the same sample in 94 cases. A highly significant correlation was found between the two indices (r = 0.85), as can be seen in Figure 8 . Eight samples showed quantitatively discordant values with SPF more than double the value of the BLI. In these cases, the immunocytochemically-stained slides were carefully inspected and only two were found to present significantly higher labelled fractions as can be seen in Figure 9 . The general comparison of BLI determinations yielded a poorer correlation than BLI (FCM) vs SPF (r = 0.75).
In order to verify the representativity of the FNS as regards tumour heterogeneity, seven patients were submitted to three samplings at weekly intervals. As shown in Figure  10 , striking differences could be observed in the DNA histo- grams. Two of the seven tumours were found diploid in all three FNS, while the remaining five were always aneuploid. However, multiploidy was observed for four patients, with variable representation of the clones in the repetitive FNS (Table II) . On the other hand, proliferation was found to be a rather stable characteristic of the tumours, as were the differences between SPF determinations and BLIs.
SPFs and BLIs were found to be highly correlated to histopathological grade (SBR) and inversely correlated to estrogen and progesterone receptor content (Table III) the art' notions in DNA-FCM, such as doublet discrimination and the use of red fluorescence peak area histograms rather than peak height (Dressler & Bartow, 1989) (Darzynkiewicz et al., 1980) . BrdU incorporation has been found to correlate quite well with 3H-thymidine labelling index in nonHodgkin's lymphoma (Silvestrini et al., 1988) . Being a nonisotopic method, BrdU labelling presents the advantage of simpler processing of specimens. We have studied BrdU incorporation in the same series of cytological samples where DNA-FCM histograms were obtained, in order to (i) The ultimate goal being to introduce proliferative activity as one of the parameters used for treatment decision, a number of conditions should be met:
(1) The assay should be easily performed in routine. This was achieved here by using a short incubation time, compatible with the duration of the FNS procedure for each patient. The quality of the staining was found excellent both after immunocytochemical staining on cytocentrifuged slides and bipametric BrdU/DNA FCM-analysis. At (2) The information should be obtained in a large majority of patients. We have shown that for the 189 consecutive patients, both SPF and BLI could be obtained in 52%, SPF alone in 26% and BLI alone in 13%, with at least one quantitative index of proliferative activity available for 91% of the patients. However, it was still to be shown whether one of the indices was sufficient to characterise the proliferative activity of a given tumour. Indeed, the frequency distributions for SPFs and BLIs were found slightly different but the difference was limited to the 70-80th percentile. This result was relatively surprising since the values for the 94 cases for which both SPF and BLI were obtained simultaneously from dual parameter cytograms, showed a good correlation (r = 0.85, P <0.0001). A possible bias introduced by the selection of samples for FCM BLI analysis based on the number of cells in hte FNS cannot be excluded. Another explanation could reside in the fact that BLIs can be determined for cases where SPF is inapplicable. Thus each index characterises a slightly different population of breast cancers.
(3) The procedure should provide reliable results. Our study revealed that whenever SPFs and BLIs were available for the same cases, their values were closely correlated. Less than 10% discordant values were observed. However, for clinical purposes a discrete classification should be more useful than continuous values. If the patients were simply classified as above or below median, six presented discordant classification and only two of these had clearly divergent values. Thus despite the slight differences in the frequency distributions, any of the two indices of proliferative activity should provide reliable information, using the appropriate cut-off values for each distribution.
Still, two questions remained concerning the adequacy of FNS for DNA and BrdU incorporation studies. The first concerns cell death induced by FNS, but the infrequent observation of cases showing SPFs considerably higher than BLI indicates a minor influence of a possible trauma caused by the FNS. The second addressed tumour heterogeneity and the representativity of sampling relative to the tumour mass. Repeated samplings were performed on seven patients, as already attempted by others (Mullen & Miller, 1989) . Modifications of the DNA histograms were observed in four out of seven, consisting in variable representation of multiple DNA peaks. Thus, multiploidy may have been underestimated in breast cancer. Although the number of patients is small, both SPF and BLI were fairly reproducible, as were the discordances between the two. This consistency of the proliferation indices, with variable representation of genetically different clones deserves further investigation regarding tissular kinetic homeostasy.
It has recently been shown that in vivo kinetic information can be obtained after BrdU infusion (Hoshino et al., 1985; Wilson et al., 1988) . The latter paper has shown that by delaying the biopsy relative to the injection, not only labelling indices but also potential doubling times can be estimated from a single sample. But our method, based on FNS, at least for breast cancer patients, may be preferable because of its simplicity and its applicability without prior diagnosis of cancer. This information on tumour proliferation, available at diagnosis should prove valuable for prognosis and treatment decision.
